VENTRIPOINT DIAGNOSTICS LTD

VentriPoint Diagnostics: 3D heart‑disease tech meets a steeply falling stock, negative P/E and market doubts. Can innovation rescue its future?

VentriPoint Diagnostics transforms 2D cardiac scans into 3D models, boosting heart‑disease diagnostics and early treatment while offering investors a growing health‑tech opportunity.

Ventripoint Diagnostics partners with Ollie Hinkle Heart Foundation to bring AI‑powered 3‑D cardiac imaging to underserved pediatric patients, expanding access and accelerating growth.

VentriPoint Diagnostics transforms 2‑D imaging into 3‑D heart models, boosting diagnostic accuracy and surgical precision for heart disease patients. Discover their innovative tech.

VentriPoint Diagnostics raises $61k CAD in shares to pay debenture interest, preserving liquidity while boosting investor confidence and supporting its AI‑cardiac diagnostics growth.

VentriPoint Diagnostics highlights unseen U.S. cardiovascular market shifts, offering investors insight into future growth and strategic opportunities in cardiac tech.

VentriPoint Diagnostics Ltd. transforms heart disease diagnosis with 3‑D imaging tech, delivering precise, cost‑effective heart models for clinicians worldwide.

VentriPoint Diagnostics Ltd. transforms heart‑disease imaging into 3‑D models, but its steep financial volatility threatens this breakthrough tech’s future.

Ventripoint Diagnostics: a low‑cost, bolt‑on 3‑D cardiac imaging solution that boosts accuracy, drives subscription revenue, and scales without new hardware—transforming hospital diagnostics.

VentriPoint Diagnostics transforms ultrasound images into 3‑D heart models, rivaling MRI quality while lowering costs. Learn how its tech and market buzz could reshape cardiac diagnostics.